PF-9363是一种强效、选择性、口服生物利用度高的KAT6A/B抑制剂，对KAT6A和KAT6B的Ki值分别为0.27nM和2.4nM。
Cas No.:2569009-58-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PF-9363 is a potent, selective, orally bioavailable KAT6A/B inhibitor with Ki values of 0.27nM and 2.4nM, respectively [1]. PF-9363 targets KAT6A/B to cause the overall loss of H3K27ac and leads to the transcriptional downregulation of genes involved in the estrogen signaling pathway, cell cycle, E2F pathway, MYC signaling pathway, and epithelial-mesenchymal transition[2]. PF-9363 has been widely used to inhibit the growth of estrogen receptor positive (ER+) breast cancer cells and to prevent tumor progression in xenograft models[3].
In vitro, PF-9363 treatment (20μM) for 14 days significantly inhibited the growth of MOLM-13 cells and reduced the abundance of H3K23ac[4]. PF-9363 (1 μM) was applied to mouse ovarian tissues for 4 days, which significantly inhibited the activation of primordial follicles, reduced the number of primordial follicles, decreased the activity of the mTOR signaling pathway, and led to an increase in the accumulation of FOXO3a in the cell nucleus[5].
In vivo, PF-9363 treatment via daily intragastric administration at a dose of 5mg/kg for 28 days significantly inhibited the tumor volume in the neuroblastoma xenograft model of NSG mice[6]. Oral administration 1mg/kg of PF-9363 every day for 3 weeks significantly inhibited the growth of Phf6 mutant-driven leukemia cells in mice, and prolonged the survival time of mice that received transplanted Phf6R274X leukemia cells[7].
References:
[1] Sharma S, Chung C Y, Uryu S, et al. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer[J]. Cell Chemical Biology, 2023, 30(10): 1191-1210. e20.
[2] Jeselsohn R, Polyak K. HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer[J]. Cell Chemical Biology, 2023, 30(10): 1183-1185.
[3] Sharma S, Chung J, Uryu S, et al. First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation[J]. Cancer Res, 2021, 81(13_Supplement): 1130.
[4] Bishop T R, Subramanian C, Bilotta E M, et al. Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition[J]. Nature chemical biology, 2023, 19(10): 1215-1222.
[5] Zhang Y, Nie X, Yang L, et al. The role of KAT6A in regulating primordial follicle activation in mouse ovary[J]. American Journal of Physiology-Cell Physiology, 2025, 329(1): C38-C49.
[6] Zimmerman M, Durbin A, Abraham B, et al. Abstract A020: Treatment of neuroblastoma with retinoic acid plus a KAT6A/B inhibitor induces sustained growth arrest and increases GD2 expression as a target for immunotherapy[J]. Cancer Research, 2025, 85(5_Supplement): A020-A020.
[7] Guo Y, Sui P, Yang H, et al. Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice[J]. Leukemia, 2026: 1-15.
PF-9363是一种强效、选择性、口服生物利用度高的KAT6A/B抑制剂，对KAT6A和KAT6B的Ki值分别为0.27nM和2.4nM[1]。PF-9363通过靶向KAT6A/B引起H3K27ac的整体缺失，并导致参与雌激素信号通路、细胞周期、E2F通路、MYC 信号通路和上皮-间质转化的基因转录下调[2]。PF-9363已被广泛用于抑制雌激素受体阳性乳腺癌细胞的生长，并阻止异种移植模型中的肿瘤进展[3]。
在体外，使用20μM的PF-9363处理MOLM-13细胞14天，显著抑制了细胞生长并降低了H3K23ac的丰度[4]。将1μM的PF-9363应用于小鼠卵巢组织4天，显著抑制了原始卵泡的激活，减少了原始卵泡数量，降低了mTOR信号通路的活性，并导致FOXO3a在细胞核内的积累增加[5]。
在体内，每日灌胃给予5mg/kg剂量的PF-9363，持续28天，显著抑制了NSG小鼠神经母细胞瘤异种移植模型中的肿瘤体积[6]。每日口服1mg/mg的PF-9363，持续3周，显著抑制了小鼠体内Phf6突变驱动的白血病细胞生长，并延长了接受Phf6R274X白血病细胞移植的小鼠的生存时间[7]。
| Cell experiment [1]: | |
Cell lines | MOLM-13 cells |
Preparation Method | MOLM-13 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin at 37℃ in the presence of 5% CO2. MOLM-13 cells were plated at a density of 2×104 cells/well in 96-well plate with growth medium for 24h, and then were incubated with the different concentrations of PF-9363 (0, 5, 10 and 20µM) for 14 days, then analyzed the cell viability. |
Reaction Conditions | 0, 5, 10 and 20µM; 14 days |
Applications | PF-9363 treatment significantly reduced the cell viability of MOLM-13 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | NSG mice |
Preparation Method | NSG mice were housed in temperature (23±2°C) and light-controlled (12:12-hour light-dark cycle) animal care facility with food and tap water ad libitum. HPB-ALL cells were cultured in RPMI-1640 medium and were xenografted into NSG mice by subcutaneous injection into the lower flank. When the tumors reached a volume of 200-250mm3, the mice were randomized into 2 groups that received either vehicle or 1mg/kg/day PF-9363 treatment by gavage. Tumor diameters were measured with digital calipers twice a week and the mice were sacrificed three-weeks after treatment. Tumor volume (mm3) was calculated using the formula: Volume = (width)2 × length/2. |
Dosage form | 1mg/kg/day for 3 weeks; p.o. |
Applications | PF-9363 treatment reduced the tumor size in HPB-ALL-bearing mice. |
References: | |
| Cas No. | 2569009-58-9 | SDF | |
| 别名 | CTx-648 | ||
| 分子式 | C20H20N4O6S | 分子量 | 444.46 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2499 mL | 11.2496 mL | 22.4992 mL |
| 5 mM | 450 μL | 2.2499 mL | 4.4998 mL |
| 10 mM | 225 μL | 1.125 mL | 2.2499 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet